GLP-1 Receptor Agonist
5mg / vial
Semaglutide is a long-acting GLP-1 receptor agonist and arguably the most intensively researched metabolic compound of the past decade. Originally developed as a treatment for type 2 diabetes, its effects on appetite regulation, insulin secretion, and body weight have made it the subject of thousands of published studies.
Semaglutide is a 94% homologous analogue of human GLP-1 (glucagon-like peptide-1), modified at positions 8 and 34 and conjugated to a C-18 fatty diacid chain via a linker. These modifications extend its half-life to approximately 7 days and enhance albumin binding, making it the longest-acting GLP-1 analogue in research use.
As a GLP-1 receptor agonist, Semaglutide stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite. Research has extensively documented its effects on glycaemic control, weight reduction, cardiovascular outcomes, and more recently, neuroinflammation and cognitive function.
Semaglutide has the most extensive published research base of any compound in our catalogue. Studies span type 2 diabetes management, obesity, cardiovascular risk reduction, non-alcoholic fatty liver disease, and emerging research in neurodegeneration and addiction.
Commonly researched with